Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany encouraged by Pfizer COVID-19 vaccine news, cautious on timeline

Mon, 09th Nov 2020 11:28

* Health ministry does not expect first vaccines before Q1
2021

* Spahn says need 55-65% of population to get vaccinated

* German experts set out first guidelines on priority groups
(Adds details from news conference with German health minister)

BERLIN, Nov 9 (Reuters) - Germany's health minister is
encouraged by a Pfizer announcement that its COVID-19
vaccine proved effective in a late-stage trial but still does
not expect a shot to be available before the first quarter of
2021, he said on Monday.

Pfizer and its German partner BioNTech said on
Monday their experimental vaccine was more than 90% effective in
preventing COVID-19 based on initial data from a large study, a
major victory in the fight against the pandemic.

"If this should prove true ... then it would be a good
signal because it shows that this vaccine makes a difference,"
Jens Spahn told a news conference, but added he was cautious on
the timeline because there can always be setbacks.

To break the dynamic of the spread of the coronavirus,
between 55% and 65% of the population will need to be
vaccinated, Spahn said. However, the first vaccines are only
expected to be available in limited amounts.

Germany plans to set up centralised vaccination centres to
inoculate priority groups in the first instance, which will be
supported by mobile teams.

First in line for vaccines should be those who are at risk
due to their age or pre-existing conditions, particularly people
living in nursing homes or long-term care facilities, the German
research centre Leopoldina and the Ethics Council said in a
position paper on priorities for vaccine delivery on Monday.

The second group should include those exposed to the virus
through their jobs, such as front-line healthcare workers, who
could also spread infections to vulnerable people.

For the third group, the experts proposed those who are
needed to maintain public life, including health authority
officials, police and security staff, firefighters and teachers.

Detailed recommendations will only be possible once
late-stage data on the characteristics of vaccines is available,
the experts said.

The German health ministry expects seven potential vaccines
to complete testing this year or next, and is anticipating the
first approvals in the first quarter of 2021, according to a
copy of its national vaccine strategy paper seen by Reuters.

Vaccination will not be mandatory. The German government
will pay for the vaccines, while the cost of setting up
vaccination centres will be borne by the states and public and
private health insurers where appropriate.

To get an overview on the effectiveness of the vaccines,
Germany will collect non-personal data including information on
age, sex, place of residence, vaccination date, vaccine product
and vaccination dose administered, the ministry paper says.
(Reporting by Andreas Rinke and Caroline Copley; Editing by
Maria Sheahan, Michelle Adair and Jan Harvey)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.